Research Theme

• Research and development of vaccines using novel CTL-inducing adjuvants and their applications

Keyword

• Tuberculosis
• Rapid diagnostic kit
• Recombinant protein large-scale expression technology

Overview of Research

• In order to commercialize a novel tuberculosis vaccine using a novel CTL-inducing adjuvant derived from Mycobacterium bovis, it is necessary to produce vaccine antigens in large quantities.
• Optimizing the antigen protein production by examining the culture method of recombinant M. smegmatis. Furthermore, we will establish a system that can purify a large amount of recombinantly expressed proteins in fewer steps.
• We will attempt to combine immune checkpoint inhibitor antibodies or their analogues with the aim of enhancing the effects of novel adjuvants in our research.
• The company uses its proprietary technology to express glycosylated proteins using Chinese hamster ovary (CHO) cells to create CHO cells that can express large amounts of immune checkpoint inhibitor antibodies or their analogues.
• Establish a system that can purify a large amount of recombinantly expressed proteins in fewer steps.